Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $14.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jamie Christensen also recently made the following trade(s):

  • On Friday, September 15th, Jamie Christensen sold 770 shares of Mirati Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $9,240.00.

Shares of Mirati Therapeutics, Inc. (NASDAQ MRTX) opened at 14.50 on Monday. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $15.40. The firm’s 50-day moving average price is $8.21 and its 200-day moving average price is $5.17. The stock’s market capitalization is $362.05 million.

TRADEMARK VIOLATION WARNING: “Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells $56,000.00 in Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/09/insider-selling-mirati-therapeutics-inc-mrtx-svp-sells-56000-00-in-stock.html.

A number of research firms recently commented on MRTX. Zacks Investment Research downgraded Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a research report on Monday, October 2nd. CIBC began coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They issued an “outperform” rating and a $18.00 target price on the stock. Citigroup Inc. reiterated a “buy” rating and issued a $16.00 target price (up from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. Finally, Cann began coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Mirati Therapeutics currently has an average rating of “Hold” and an average price target of $12.63.

Institutional investors have recently modified their holdings of the company. Royce & Associates LP boosted its holdings in shares of Mirati Therapeutics by 88.7% during the 2nd quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after purchasing an additional 118,063 shares during the last quarter. Broadfin Capital LLC boosted its holdings in shares of Mirati Therapeutics by 153.1% during the 1st quarter. Broadfin Capital LLC now owns 2,090,801 shares of the biotechnology company’s stock worth $10,872,000 after purchasing an additional 1,264,800 shares during the last quarter. Omega Advisors Inc. acquired a new position in shares of Mirati Therapeutics during the 1st quarter worth approximately $520,000. Bank of New York Mellon Corp boosted its holdings in shares of Mirati Therapeutics by 22.9% during the 1st quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 11,753 shares during the last quarter. Finally, Trexquant Investment LP boosted its holdings in shares of Mirati Therapeutics by 62.2% during the 1st quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 16,447 shares during the last quarter. Institutional investors and hedge funds own 60.17% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.